Join Prof Iain McInnes as he reviews two interesting papers.
Our first paper today by Roy Fleischmann and his colleagues compares the incidence of serious adverse events in RA patients with a higher risk of cardiovascular events and the overall RA population in a post-hoc study. They also compared the incidence rate of adverse events for upadacitinib, adalimumab and methotrexate, or methotrexate monotherapy.
In our second paper, Mohammed Khan and colleagues compared tofacitinib against methotrexate as first-line therapies against RA, with a focus on treatment remission.
